Drug discovery without pharmacology is alchemy—full of hope but devoid of predictability. The pharmacologist’s mantra echoes through every phase of development:
Drug discovery begins with a disease hypothesis. Pharmacology steps in to validate the biological target—typically a receptor, enzyme, ion channel, or nucleic acid. Using tools like CRISPR-Cas9, RNA interference, and monoclonal antibodies, pharmacologists confirm that modulating this target will indeed produce a therapeutic effect.
Proving a protein or receptor causes the disease.
If a compound shows promise in preclinical studies, it advances to the clinical phase, where it is tested in humans. Pharmacology continues to play a vital role in this phase by:
The classical view of pharmacology (one drug, one receptor, one disease) is obsolete. Modern pharmacology is tackling complexity.
Pharmacology provides the biomarkers that measure target engagement. For example, in cancer drug development, measuring phosphorylated AKT in a tumor biopsy proves that a novel PI3K inhibitor is hitting its target. Without such pharmacology-driven evidence, a failed trial might be due to poor target engagement rather than a bad therapeutic concept.
Drug discovery without pharmacology is alchemy—full of hope but devoid of predictability. The pharmacologist’s mantra echoes through every phase of development:
Drug discovery begins with a disease hypothesis. Pharmacology steps in to validate the biological target—typically a receptor, enzyme, ion channel, or nucleic acid. Using tools like CRISPR-Cas9, RNA interference, and monoclonal antibodies, pharmacologists confirm that modulating this target will indeed produce a therapeutic effect. pharmacology in drug discovery and development
Proving a protein or receptor causes the disease. Pharmacology continues to play a vital role in
If a compound shows promise in preclinical studies, it advances to the clinical phase, where it is tested in humans. Pharmacology continues to play a vital role in this phase by: in cancer drug development
The classical view of pharmacology (one drug, one receptor, one disease) is obsolete. Modern pharmacology is tackling complexity.
Pharmacology provides the biomarkers that measure target engagement. For example, in cancer drug development, measuring phosphorylated AKT in a tumor biopsy proves that a novel PI3K inhibitor is hitting its target. Without such pharmacology-driven evidence, a failed trial might be due to poor target engagement rather than a bad therapeutic concept.